Both legacy players and startups have an important role to play when it comes to medical innovation—they need to work together to meet the increasing demand for minimally invasive treatments, value-based care and innovative, not incremental therapies. This is a mutually beneficial relationship that is key to medical technology development.
You’d think there’s not much to the concept of an alarm. A warning sounds in a room, or a red light flashes, and it has your attention. You know something must be wrong. But in a setting where a cacophony of alarming lights and sounds beset healthcare workers on a regular basis, these essential systems become increasingly easy to miss or ignore.
2022 is now upon us, hopefully marking the end of a very disruptive couple of years. Global challenges, from supply chain shortages to remote services, have driven digital innovation and change in the way we work across all sectors. The medical device industry is no different and going forward, having learned from the experiences of 2021.
This year, the healthcare industry will step up its fight against cyberattacks because the costs and risks to patient care are becoming too great.
There is significant opportunity to develop therapies that create new standards of care and initiate a new wave of precision medicine.
Five steps to better protect providers, medtech companies, their networks, data and patients from a cyberattack.
Building fruitful development partnerships between companies, governments and researchers will enable the most promising and impactful deployments in healthcare.
A global pandemic is still upon us, but that certainly does not mean that healthcare technology innovation is standing still. To help the medical device industry look to the future and prepare, experts from regulation and academia alike are bringing attention to the acceleration and pitfalls of innovation.
Healthcare cannot remain reactive to dealing with cybersecurity risks. We must take a new, proactive approach to protecting our users, and our systems must prioritize reducing the extent of reliance on users against unknown threats.
Although the future is exciting, it also poses real challenges. More collaborative initiatives need to take place between drug manufacturers and developers of manufacturing equipment and consumables.
